Race Oncology Ltd has released a press release.
Race Initiates Extramedullary AML Preclinical Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Initiates FTO Directed Kidney Cancer Preclinical Study
- Race Initiates FTO Melanoma Preclinical Study
- S&P DJI Announces March 2021 Quarterly Rebalance
- Compelling Preclinical Breast Cancer Results
- Race receives $387k R&D tax incentive refund
Later from Racura Oncology
- Race Strategic Update March 2021
- Second independent study shows Bisantrene inhibits FTO
- Race Initiates Heart Safety Preclinical Study for Bisantrene
- Race investor briefing & updated presentation
- Placement closes oversubscribed-Bonus Option Issue launched
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology